Cardiovascular disease risk and pathophysiology in South Asians: Can longitudinal multi-omics shed light?

• Authors: Arshed Quyyumi, Emory University; Kabayam Venkat Narayan, Emory University; Yan Sun, Emory University; Mohammed Ali, Emory University; Dean Jones, Emory University; Howard Chang, Emory University; Lisa Staimez, Emory University; Shivani Patel, Emory University; Dorairaj Prabhakaran, Emory University; Dimple Kondal, Emory University; C Liu, Rollins School of Public Health; V Mohan, Madras Diabetes Research Foundation; N Tandon, All India Institute of Medical Sciences, New Delhi; KMV Narayan, Rollins School of Public Health; A Agrawal, Institute of Genomics and Integrative Biology India
• Journal Title: Wellcome Open Research
• Volume: Volume 5, Number
• Publisher: (publisher) | 2021-01-01, Pages 255-255
• Type of Work: Article
• Publisher DOI: http://doi.org/10.12688/wellcomeopenres.16336.2
• Keywords: HFpEF; HFrEF; South Asians; atherosclerosis; diabetes; heart failure; multi-omics; subclinical CVD

Abstract

Cardiovascular disease (CVD) is the leading cause of mortality in South Asia, with rapidly increasing prevalence of hypertension, type 2 diabetes (T2DM) and hyperlipidemia over the last two decades. Atherosclerotic CVD (ASCVD) affects South Asians earlier in life and at lower body weights, which is not fully explained by differential burden of conventional risk factors. Heart failure (HF) is a complex clinical syndrome of heterogeneous structural phenotypes including two major clinical subtypes, HF with preserved (HFpEF) and reduced ejection fraction (HFrEF). The prevalence of HF in South Asians is also rising with other metabolic diseases, and HFpEF develops at younger age and leaner body mass index in South Asians than in Whites. Recent genome-wide association studies, epigenome-wide association studies and metabolomic studies of ASCVD and HF have identified genes, metabolites and pathways associated with CVD traits. However, these findings were mostly driven by samples of European ancestry, which may not accurately represent the CVD risk at the molecular level, and the unique risk profile of CVD in South Asians. Such bias, while formulating hypothesis-driven research studies, risks missing important causal or predictive factors unique to South Asians. Importantly, a longitudinal design of multi-omic markers can capture the life-course risk and natural history related to CVD, and partially disentangle putative causal relationship between risk factors, multi-omic markers and subclinical and clinical ASCVD and HF. In conclusion, combining high-resolution untargeted metabolomics with epigenomics of rigorous, longitudinal design will provide comprehensive unbiased molecular characterization of subclinical and clinical CVD among South Asians. A thorough understanding of CVD-associated metabolomic profiles, together with advances in epigenomics and genomics, will lead to more accurate estimates of CVD progression and stimulate new strategies for improving cardiovascular health.